BioCentury
ARTICLE | Management Tracks

Goeltz to join Arcus as CFO following Gilead deal; plus changes at Corbus, MyoKardia, Humanigen, Aimmune, Avrobio, Syndax and more

July 9, 2020 1:11 AM UTC

Arcus Biosciences Inc. (NYSE:RCUS), named Bob Goeltz as CFO, effective August 1. Goeltz, who was SVP and CFO of Unity Biotechnology Inc. (NASDAQ:UBX), succeeds CFO and COO Rekha Hemrajani. In May, Gilead Sciences Inc. (NASDAQ:GILD) paid $175 million up front for exclusive rights to Arcus’ PD-1 inhibitor and options to the remainder of the cancer company’s pipeline (see “Arcus Keeps Independence in Gilead Deal”).

George Golumbeski joined the board of inflammatory and autoimmune diseases company Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP). Golumbeski is a partner at Arch Venture Partners and was EVP of business development at Celgene Corp. in 2009-18...